IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/ane-logistics" target="_blank" data-smartkarma-citation="entities:34119:1" rel="noopener">ANE Logistics (1292621D CH)</a> operates a leading express freight network in China’s less-than-truckload (LTL) market. ANE operated the largest express freight network in China as measured by annual total freight volume in each of 2017, 2018, 2019 and 2020, according to iResearch.</p><p>ANE is pre-marketing an HKEx IPO to raise up to $500 million, according to press reports. ANE’s shareholders include Centurium, Carlyle, CDH, CPE, NWS, Ping An, Goldman Sachs and Yili.</p><p>In <a href="https://www.smartkarma.com/insights/ane-logistics-ipo-initiation-home-delivery" target="_blank" data-smartkarma-citation="insights:57807" rel="noopener">ANE Logistics IPO Initiation: Home Delivery</a>, we stated that ANE is a play on China’s LTL market which offers substantial opportunities for market consolidation as the top 10 LTL operators in China had a market share of 5.7% by shipper spend in 2020, according to iResearch. As the largest (by freight volume), fastest-growing and most profitable player, ANE is well-positioned to be a market consolidator. We concluded that ANE’s fundamentals are solid. </p><div class="content-highlight"><p>In this note, we look at the PHIP which discloses the 4M21 results and recent developments. The PHIP continues to support our view that the ANE IPO is worth a look for investors willing to brave the current weak sentiment on HKEx IPOs.</p></div>

ANE Logistics (1292621D CH) operates a leading express freight network in China’s less-than-truckload (LTL) market. ANE operated the largest express freight network in China as measured by annual total freight volume in each of 2017, 2018, 2019 and 2020, according to iResearch.ANE is pre-marketing an HKEx IPO to raise up to $500 million, according to press reports. ANE’s shareholders include Centurium, Carlyle, CDH, CPE, NWS, Ping An, Goldman Sachs and Yili.In ANE Logistics IPO Initiation: Home Delivery, we stated that ANE is a play on China’s LTL market which offers substantial opportunities for market consolidation as the top 10 LTL operators in China had a market share of 5.7% by shipper spend in 2020, according to iResearch. As the largest (by freight volume), fastest-growing and most profitable player, ANE is well-positioned to be a market consolidator. We concluded that ANE’s fundamentals are solid. In this note, we look at the PHIP which discloses the 4M21 results and recent developments. The PHIP continues to support our view that the ANE IPO is worth a look for investors willing to brave the current weak sentiment on HKEx IPOs.

<p><a href="https://www.smartkarma.com/entities/ane-logistics" target="_blank" data-smartkarma-citation="entities:34119:1" rel="noopener">ANE Logistics (1292621D CH)</a> operates a leading express freight network in China’s less-than-truckload (LTL) market. ANE operated the largest express freight network in China as measured by annual total freight volume in each of 2017, 2018, 2019 and 2020, according to iResearch.</p><p>ANE passed its HKEx listing committee hearing and will start pre-marketing to raise up to $500 million, according to press reports. ANE’s shareholders include Centurium, <a href="https://www.smartkarma.com/entities/carlyle-group-inc" target="_blank" data-smartkarma-citation="entities:33402:1" rel="noopener">Carlyle Group Inc (CG US)</a>, CDH, CPE, <a href="https://www.smartkarma.com/entities/nws-holdings-ltd" target="_blank" data-smartkarma-citation="entities:3350:1" rel="noopener">Nws Holdings (659 HK)</a>, Ping An, <a href="https://www.smartkarma.com/entities/goldman-sachs-group-inc" target="_blank" data-smartkarma-citation="entities:785:1" rel="noopener">Goldman Sachs Group (GS US)</a> and <a href="https://www.smartkarma.com/entities/inner-mongolia-yili-indus-a" target="_blank" data-smartkarma-citation="entities:3220:1" rel="noopener">Inner Mongolia Yili Industrial Group (A) (600887 CH)</a>.</p><div class="content-highlight"><p>ANE is a play on China’s LTL market which offers substantial opportunities for market consolidation as the top 10 LTL operators in China had a market share of 5.7% by shipper spend in 2020, according to iResearch. As the largest (by freight volume), fastest-growing and most profitable player, ANE is well-positioned to be a market consolidator. On balance, we think that ANE’s fundamentals are solid and the IPO is worth a look for investors willing to brave the current weak sentiment on HKEx IPOs. </p></div>

ANE Logistics (1292621D CH) operates a leading express freight network in China’s less-than-truckload (LTL) market. ANE operated the largest express freight network in China as measured by annual total freight volume in each of 2017, 2018, 2019 and 2020, according to iResearch.ANE passed its HKEx listing committee hearing and will start pre-marketing to raise up to $500 million, according to press reports. ANE’s shareholders include Centurium, Carlyle Group Inc (CG US), CDH, CPE, Nws Holdings (659 HK), Ping An, Goldman Sachs Group (GS US) and Inner Mongolia Yili Industrial Group (A) (600887 CH).ANE is a play on China’s LTL market which offers substantial opportunities for market consolidation as the top 10 LTL operators in China had a market share of 5.7% by shipper spend in 2020, according to iResearch. As the largest (by freight volume), fastest-growing and most profitable player, ANE is well-positioned to be a market consolidator. On balance, we think that ANE’s fundamentals are solid and the IPO is worth a look for investors willing to brave the current weak sentiment on HKEx IPOs. 

ANE Logistics IPO Initiation: Home Delivery

ASEAN Insight Provider, CrossASEAN Research

Angus Mackintosh

ASEAN Insight Provider

CrossASEAN Research

At CrossASEAN Research we strive to produce unbiased and differentiated on the ground insights on companies across South East Asia. Our Research is produced for the most part after face to face meetings and conversations with company management to dig deep into the long term vision and strategy of the companies we cover. We seek to deliver investable and actionable themes on sectors and markets across SE Asia, often in collaboration with other Insight Providers across the region, pooling the vast experience of the analysts within the Smartkarma Ecosystem. We also offer bespoke work and tailor made trips for our clients. 

Insights across South East Asia

Equity Bottom-Up

<div class="content-highlight">
<p><a href="https://www.smartkarma.com/entities/adi-sarana-armada-tbk-pt" target="_blank" data-smartkarma-citation="entities:16947:1" rel="noopener">Adi Sarana Armada (ASSA IJ)</a> released a stellar set of 1Q2021 results, with revenue growth of +37.3% YoY, and net profit growth of +27.1% YoY, which continued to reflect better than expected growth in its end-to-end logistics business, and notably Anteraja, its last-mile delivery service.</p>
</div>
<p>The company's three pillars including transport, car auction, and end-to-end logistics, all registered strong growth. The company's last-mile express delivery service Anteraja saw especially strong growth driven by the e-commerce ecosystem as it is providing deliveries for most of the major players. </p>
<p>Anteraja's continues to expand its business, with daily parcel deliveries hitting 500,000 in 1Q2021 and targets 700,000-750,000 parcels a day by the end of the year.</p>
<section class="figure"></section>
<section class="figure"><a href="https://www.smartkarma.com/entities/adi-sarana-armada-tbk-pt" target="_blank" data-smartkarma-citation="entities:16947:1" rel="noopener">Adi Sarana Armada (ASSA IJ)</a>'s auction business also recorded positive revenue growth of +3.8%  in 1Q2021 but has seen a recent pick up in growth. </section>
<section class="figure"></section>
<section class="figure"></section>
<section class="figure"></section>
<section class="figure"><a href="https://www.smartkarma.com/entities/adi-sarana-armada-tbk-pt" target="_blank" data-smartkarma-citation="entities:16947:1" rel="noopener"></a>The company continues to develop its app-based businesses such as Share Car and used car marketplace, Caroline.</section>
<section class="figure"></section>
<section class="figure"></section>
<section class="figure"></section>
<section class="figure"></section>
<div>
<p><a href="https://www.smartkarma.com/entities/adi-sarana-armada-tbk-pt" target="_blank" data-smartkarma-citation="entities:16947:1" rel="noopener">Adi Sarana Armada (ASSA IJ)</a> targets revenue growth 0f +20%-25% for 2021 mainly driven by the growth from end-to-end logistics and specifically Anteraja, together with e-commerce sharing warehouse Titipaja. </p>
</div>
<p>The company also recently had its rights issue of zero-coupon convertible bonds approved, which will raise a total of IDR720bn. This will help the company reduce the debt used to expand its logistics businesses over the past year.</p>
<p>We continue to believe in the <a href="https://www.smartkarma.com/entities/adi-sarana-armada-tbk-pt" target="_blank" data-smartkarma-citation="entities:16947:1" rel="noopener">Adi Sarana Armada (ASSA IJ)</a> digital transformation story, with ongoing synergies between the three pillars of its business.</p>
<p><a href="https://www.smartkarma.com/entities/adi-sarana-armada-tbk-pt" target="_blank" data-smartkarma-citation="entities:16947:1" rel="noopener">Adi Sarana Armada (ASSA IJ)</a> trades on 10.9x FY21E EV/EBITDA and 8.7x FY22E EV/EBITDA and an FY22E PER of 30x but we expect continuing momentum behind the growth and rising profitability story, as Anteraja gains scale and grows its revenues.</p>
<section class="figure"></section>
<section class="figure">
<section class="figure"></section>
<div id="ember5694"></div>
</section>


Adi Sarana Armada (ASSA IJ) released a stellar set of 1Q2021 results, with revenue growth of +37.3% YoY, and net profit growth of +27.1% YoY, which continued to reflect better than expected growth in its end-to-end logistics business, and notably Anteraja, its last-mile delivery service.

The company's three pillars including transport, car auction, and end-to-end logistics, all registered strong growth. The company's last-mile express delivery service Anteraja saw especially strong growth driven by the e-commerce ecosystem as it is providing deliveries for most of the major players. 
Anteraja's continues to expand its business, with daily parcel deliveries hitting 500,000 in 1Q2021 and targets 700,000-750,000 parcels a day by the end of the year.

Adi Sarana Armada (ASSA IJ)'s auction business also recorded positive revenue growth of +3.8%  in 1Q2021 but has seen a recent pick up in growth. 



The company continues to develop its app-based businesses such as Share Car and used car marketplace, Caroline.





Adi Sarana Armada (ASSA IJ) targets revenue growth 0f +20%-25% for 2021 mainly driven by the growth from end-to-end logistics and specifically Anteraja, together with e-commerce sharing warehouse Titipaja. 

The company also recently had its rights issue of zero-coupon convertible bonds approved, which will raise a total of IDR720bn. This will help the company reduce the debt used to expand its logistics businesses over the past year.
We continue to believe in the Adi Sarana Armada (ASSA IJ) digital transformation story, with ongoing synergies between the three pillars of its business.
Adi Sarana Armada (ASSA IJ) trades on 10.9x FY21E EV/EBITDA and 8.7x FY22E EV/EBITDA and an FY22E PER of 30x but we expect continuing momentum behind the growth and rising profitability story, as Anteraja gains scale and grows its revenues.






Adi Sarana Armada (ASSA IJ) - End-To End Aspirations on Track

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

<div>
<p><a href="https://www.smartkarma.com/entities/xpeng-motors" target="_blank" data-smartkarma-citation="entities:29217:1" rel="noopener">Xpeng Motors (XPEV US)</a> raised around US$2bn via a listing in Hong Kong. In this note, we will talk about the trading dynamics and the updates since our last note, <a href="https://www.smartkarma.com/insights/xpeng-motors-hk-listing-will-probably-be-hot-given-strong-momentum-but-past-deal-didn-t-do-well" target="_blank" rel="noopener">Xpeng Motors HK Listing - Will Probably Be Hot Given Strong Momentum but past Deal Didn’t Do Well.</a></p>
</div>
<div>
<p>We have covered the IPO in:</p>
</div>
<div>
<ul style="list-style-type: disc;">
<li>
<a href="https://www.smartkarma.com/insights/xpeng-motors-pre-ipo-lots-to-like-with-solid-backing-from-investors" target="_blank" data-smartkarma-citation="insights:42126" rel="noopener">Xpeng Motors (小鹏汽车) Pre-IPO - Lots to like with Solid Backing from Investors</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/xpeng-motors-visited-a-store-fairly-priced-but-with-recharging-problem" target="_blank" data-smartkarma-citation="insights:42283" rel="noopener">Xpeng Motors (小鹏汽车): Visited a Store, Fairly Priced, But with Recharging Problem</a> </li>
<li><a href="https://www.smartkarma.com/insights/xpeng-motors-pre-ipo-car-comparison-and-p7-performance-test" target="_blank" data-smartkarma-citation="insights:42386" rel="noopener">Xpeng Motors (小鹏汽车) Pre-IPO - Car Comparison and P7 Performance Test</a></li>
<li>
<a href="https://www.smartkarma.com/insights/xpeng-motors-pre-ipo-peer-comparison-and-valuation" target="_blank" data-smartkarma-citation="insights:42389" rel="noopener">Xpeng Motors (小鹏汽车) Pre-IPO - Peer Comparison and Valuation</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/xpeng-ipo-riding-the-momentum" target="_blank" data-smartkarma-citation="insights:42503" rel="noopener">Xpeng Motors (小鹏汽车) IPO - Riding the Momentum</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/xpeng-motors-trading-nio-leading-the-charge" target="_blank" data-smartkarma-citation="insights:42616" rel="noopener">Xpeng Motors (小鹏汽车) Trading - NIO Leading the Charge</a> </li>
</ul>
</div>
<div>
<p>And the previous placement in:</p>
</div>
<div>
<ul style="list-style-type: disc;">
<li><a href="https://www.smartkarma.com/insights/xpeng-motors-placement-level-the-playing-field" target="_blank" rel="noopener">Xpeng Motors (小鹏汽车) Placement - Level the Playing Field</a></li>
</ul>
</div>


Xpeng Motors (XPEV US) raised around US$2bn via a listing in Hong Kong. In this note, we will talk about the trading dynamics and the updates since our last note, Xpeng Motors HK Listing - Will Probably Be Hot Given Strong Momentum but past Deal Didn’t Do Well.


We have covered the IPO in:




Xpeng Motors (小鹏汽车) Pre-IPO - Lots to like with Solid Backing from Investors 

Xpeng Motors (小鹏汽车): Visited a Store, Fairly Priced, But with Recharging Problem 
Xpeng Motors (小鹏汽车) Pre-IPO - Car Comparison and P7 Performance Test

Xpeng Motors (小鹏汽车) Pre-IPO - Peer Comparison and Valuation 

Xpeng Motors (小鹏汽车) IPO - Riding the Momentum 

Xpeng Motors (小鹏汽车) Trading - NIO Leading the Charge 



And the previous placement in:



Xpeng Motors (小鹏汽车) Placement - Level the Playing Field



Xpeng Motors HK Trading - More Hot with Instis that Retail

Hutchmed China Ltd / Equity Capital Markets

<div>
<p><a href="https://www.smartkarma.com/entities/hutchmed-china-ltd" target="_blank" data-smartkarma-citation="entities:133:1" rel="noopener">Hutchmed China Ltd (13 HK)</a> has launched a $603 million secondary listing on HKEx by offering 104.0 million ordinary shares at a maximum offer price of HK$45.00 per share. Bookbuilding is scheduled to run until the pricing on 23 June. The net proceeds will be used to fund the late-stage clinical programs (<em>savolitinib, surufatinib, fruquintinib</em>, HMPL-689 and HMPL-523), to support further proof-of-concept studies and strengthen commercialisation capabilities.</p>
<p>HutchMed has primary listings on Nasdaq and on UK AIM. The HKEx secondary listing will be supported by five cornerstone investors which will subscribe for HK$2,535 million ($325 million) of the offer shares (54.17% of the offer shares at the maximum offer price). The cornerstone investors are <a href="https://www.smartkarma.com/entities/carlyle-group-inc" target="_blank" data-smartkarma-citation="entities:33402:1" rel="noopener">Carlyle Group Inc (CG US)</a>, CPP Investments, General Atlantic, <a href="https://www.smartkarma.com/entities/hbm-healthcare-investments-ag" target="_blank" data-smartkarma-citation="entities:22373:1" rel="noopener">HBM Healthcare Investments AG (HBMN SW)</a> and CICC Capital.</p>
<p>HutchMed is a China-based, globally focused, biopharma company, active in discovery, development, manufacturing, and commercialisation. The investment case centres on the<br>success of its oncology/immunology platform, which has several near-term clinical and regulatory catalysts from the novel highly selective small molecule (tyrosine kinase inhibitor) pipeline. Notably, in-house discovered drugs, <em>Elunate (fruquintinib)</em> and <em>Sulanda (surufatinib)</em>, together with a likely approval for <em>savolitinib</em>, are transforming China prospects. <em>Elunate</em> is performing well in China, with NRDL inclusion boosting volumes. The first global launch is likely to be <em>surufatinib </em>with a US launch targeted for late 2021 or early 2022.</p>
</div><div><div class="content-highlight"><p>In this note, we will look at HutchMed’s potential HK-ADS premium/(discount). As per the norm, HutchMed will price its H-shares at a discount to its ADSs/UK shares to entice investors to participate in the secondary listing. HutchMed pricing its H-shares at a discount of 2-3% to its ADSs will be reasonable, in our view.</p></div></div>


Hutchmed China Ltd (13 HK) has launched a $603 million secondary listing on HKEx by offering 104.0 million ordinary shares at a maximum offer price of HK$45.00 per share. Bookbuilding is scheduled to run until the pricing on 23 June. The net proceeds will be used to fund the late-stage clinical programs (savolitinib, surufatinib, fruquintinib, HMPL-689 and HMPL-523), to support further proof-of-concept studies and strengthen commercialisation capabilities.
HutchMed has primary listings on Nasdaq and on UK AIM. The HKEx secondary listing will be supported by five cornerstone investors which will subscribe for HK$2,535 million ($325 million) of the offer shares (54.17% of the offer shares at the maximum offer price). The cornerstone investors are Carlyle Group Inc (CG US), CPP Investments, General Atlantic, HBM Healthcare Investments AG (HBMN SW) and CICC Capital.
HutchMed is a China-based, globally focused, biopharma company, active in discovery, development, manufacturing, and commercialisation. The investment case centres on the success of its oncology/immunology platform, which has several near-term clinical and regulatory catalysts from the novel highly selective small molecule (tyrosine kinase inhibitor) pipeline. Notably, in-house discovered drugs, Elunate (fruquintinib) and Sulanda (surufatinib), together with a likely approval for savolitinib, are transforming China prospects. Elunate is performing well in China, with NRDL inclusion boosting volumes. The first global launch is likely to be surufatinib with a US launch targeted for late 2021 or early 2022.
In this note, we will look at HutchMed’s potential HK-ADS premium/(discount). As per the norm, HutchMed will price its H-shares at a discount to its ADSs/UK shares to entice investors to participate in the secondary listing. HutchMed pricing its H-shares at a discount of 2-3% to its ADSs will be reasonable, in our view.

HutchMed Secondary Listing: HK-ADS Premium/​​​(Discount) Views

China

ZTO Express (Cayman) Inc. operates as an express delivery company. The Company provides express delivery service through their nationwide network, as well as other value-added logistics services. ZTO Express serves customers globally.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ZTO Express Cayman (ZTO US)

ANE IPO: The Freight Debate

ANE is pre-marketing an HKEx IPO to raise up to $500 m. The PHIP continues to support our view that the ANE is worth a look for investors willing...

Arun George

ANE Logistics IPO Initiation: Home Delivery

ANE will start pre-marketing an HKEx IPO to raise up to $500 m. We think that ANE’s fundamentals are solid and the IPO is worth a look for...

Arun George

Adi Sarana Armada (ASSA IJ) - End-To End Aspirations on Track

ASSA remains a high-growth Indonesian transport and logistics player, which is increasingly driven by the rapid growth of its last-mile delivery...

Angus Mackintosh

Xpeng Motors HK Trading - More Hot with Instis that Retail

Xpeng Motors (XPEV US) raised around US$2bn via a listing in Hong Kong. In this note, we will talk about the trading dynamics and the updates since...

Sumeet Singh

HutchMed Secondary Listing: HK-ADS Premium/(Discount) Views

HutchMed has launched a $603 million secondary listing on HKEx. In this note, we will look at HutchMed’s potential HK-ADS premium/(discount).

Arun George

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

ANE IPO: The Freight Debate

ANE is pre-marketing an HKEx IPO to raise up to $500 m. The PHIP continues to support our view that the ANE is worth a look for investors willing...

Arun George

ANE Logistics IPO Initiation: Home Delivery

ANE will start pre-marketing an HKEx IPO to raise up to $500 m. We think that ANE’s fundamentals are solid and the IPO is worth a look for...

Arun George

Adi Sarana Armada (ASSA IJ) - End-To End Aspirations on Track

ASSA remains a high-growth Indonesian transport and logistics player, which is increasingly driven by the rapid growth of its last-mile delivery...

Angus Mackintosh

Xpeng Motors HK Trading - More Hot with Instis that Retail

Xpeng Motors (XPEV US) raised around US$2bn via a listing in Hong Kong. In this note, we will talk about the trading dynamics and the updates since...

Sumeet Singh

HutchMed Secondary Listing: HK-ADS Premium/​​​(Discount) Views

HutchMed has launched a $603 million secondary listing on HKEx. In this note, we will look at HutchMed’s potential HK-ADS premium/(discount).

Arun George

HutchMed Secondary Listing: HK-ADS Premium/(Discount) Views